Prognostic Significance of Blood Transfusion in Newly Diagnosed Multiple Myeloma Patients without Autologous Hematopoietic Stem Cell Transplantation

Table 3

Multivariate analysis of the correlation between demographic and clinicopathological characteristics and survival time in patients with MM.

Covariates	Overall survival		Progression-free survival
	95% CI for HR		95% CI for HR
Age	1.005–1.038	0.011	N/A	N/A
Ig isotype	N/A	N/A	0.659–0.957	0.015
ISS staging	0.697–1.661	0.740	0.694–1.648	0.761
Plt (×10^9/L)	0.369–0.939	0.026	0.409–1.084	0.102
Scr (μmol/L)	0.977–2.453	0.063	0.975–2.501	0.063
-MG (μmol/L)	0.665–2.524	0.447	0.849–3.244	0.138
Ca (mmol/L)	1.172–3.389	0.011	0.838–2.279	0.205
Thalidomide	0.277–0.612	0.000	0.286–0.641	0.000
Blood transfusion	N/A	N/A	0.735–1.453	0.849

ISS: International Staging System; Scr: serum creatinine; β₂-MG: β₂-microglobulin; Ca: calcium; HR: hazard ratio; CI: confidence interval; N/A: not available.